Literature DB >> 30140647

A review of combined phacoemulsification and endoscopic cyclophotocoagulation: efficacy and safety.

Wen Sun1, Chen-Ying Yu1, Jian-Ping Tong1.   

Abstract

As cataract occurs frequently in patients with glaucoma, combining phacoemulsification and endoscopic cyclophotocoagulation has been gaining attention recently due to its minimally invasive nature. A variety of studies had evaluated the efficacy and safety of this procedure and had shown extremely promising results. This review article has shown here that combined phacoemulsification and endoscopic cyclophotocoagulation procedure could effectively reduce intraocular pressure in medically uncontrolled glaucoma patients while avoiding serious complications associated with traditional cyclophotocoagulation procedure and adverse effects related to filtering surgery such as trabeculectomy.

Entities:  

Keywords:  endoscopic cyclophotocoagulation; glaucoma; phacoemulsification

Year:  2018        PMID： 30140647      PMCID： PMC6090118          DOI： 10.18240/ijo.2018.08.23

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN： 2222-3959            Impact factor:   1.779


  43 in total

1.  Combined cataract and glaucoma surgery: trabeculectomy versus endoscopic laser cycloablation.

Authors:  J L Gayton; M Van Der Karr; V Sanders
Journal:  J Cataract Refract Surg       Date:  1999-09       Impact factor: 3.351

Review 2.  Management of coincident cataract and glaucoma.

Authors:  T W Samuelson
Journal:  Curr Opin Ophthalmol       Date:  1993-02       Impact factor: 3.761

3.  Diode laser endoscopic cyclophotocoagulation in the normal equine eye.

Authors:  Jay T Harrington; Richard J McMullen; John M Cullen; Nigel B Campbell; Brian C Gilger
Journal:  Vet Ophthalmol       Date:  2012-05-29       Impact factor: 1.644

4.  Refractive outcome of combined phacoemulsification and endoscopic cyclophotocoagulation.

Authors:  S Kang; S Luk; H Han; M F Cordeiro; F Ahmed; P Bloom; L Crawley
Journal:  Int Ophthalmol       Date:  2016-12-19       Impact factor: 2.031

5.  [Complications of goniosynechialysis. Special reference to fibrin-like exudate].

Authors:  H Tanihara; M Nagata
Journal:  Nippon Ganka Gakkai Zasshi       Date:  1988-03

6.  Combined phacoemulsification and goniosynechialysis for uncontrolled chronic angle-closure glaucoma after acute angle-closure glaucoma.

Authors:  C Teekhasaenee; R Ritch
Journal:  Ophthalmology       Date:  1999-04       Impact factor: 12.079

7.  Endoscopic diode laser cyclophotocoagulation with a limbal approach.

Authors:  J S Mora; A G Iwach; M M Gaffney; P C Wong; N Nguyen; A S Ma; C J Dickens
Journal:  Ophthalmic Surg Lasers       Date:  1997-02

8.  Endoscopic diode laser cyclophotocoagulation in the management of aphakic and pseudophakic glaucoma in children.

Authors:  B Christian Carter; David A Plager; Daniel E Neely; Derek T Sprunger; Naval Sondhi; Gavin J Roberts
Journal:  J AAPOS       Date:  2006-11-02       Impact factor: 1.220

9.  Endoscopic cyclophotocoagulation combined with phacoemulsification versus phacoemulsification alone in medically controlled glaucoma.

Authors:  Brian A Francis; Stanley J Berke; Laurie Dustin; Robert Noecker
Journal:  J Cataract Refract Surg       Date:  2014-08       Impact factor: 3.351

Review 10.  Endoscopic cyclophotocoagulation.

Authors:  S Lin
Journal:  Br J Ophthalmol       Date:  2002-12       Impact factor: 4.638
View more
  2 in total

1.  Endoscopic Cyclophotocoagulation Combined with Phacoemulsification Increases Risk of Persistent Anterior Uveitis Compared to Phacoemulsification Surgery Alone.

Authors:  Vivek A Koduri; Amit K Reddy; Jennifer L Patnaik; Alan G Palestine; Anne M Lynch; Mina B Pantcheva
Journal:  Clin Ophthalmol       Date:  2021-02-05

2.  Phaco-UCP; combined phacoemulsification and ultrasound ciliary plasty versus phacoemulsification alone for management of coexisting cataract and open angle glaucoma: a randomized clinical trial.

Authors:  Magda A Torky; Yousef A Alzafiri; Ameera G Abdelhameed; Eman A Awad
Journal:  BMC Ophthalmol       Date:  2021-01-21       Impact factor: 2.209
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.